⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 23, 2024Current Eye ResearchOpen Access

Cost-Effectiveness Analysis of Adalimumab Versus Cyclosporine for Vogt-Koyanagi-Harada Disease: A Randomized Controlled Study

Lingyu Dai Zhenyu Zhong Qiuying Wu Yu Gao Xiaorong Lu Fuxiang Zhang Chong Tang Yao Wang Chunjiang Zhou Peizeng Yang

View Full Paper

Ask AI

Bookmark

Share

Abstract

To compare the 26-week cost-effectiveness of adalimumab-corticosteroids (ADA-CS) and cyclosporine-corticosteroids (CSA-CS) for Vogt-Koyanagi-Harada (VKH).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dai et al. (2024) studied this question.

synapsesocial.com/papers/68e68cfdb6db643587614b1c https://doi.org/10.1080/02713683.2024.2355659

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease2024 · 7 citations
2Clinical and Transcriptional Profiles Reveal the Treatment Effect of Adalimumab in Patients with Initial-Onset and Recurrent Vogt–Koyanagi–Harada Disease2024 · 1 citations
3Efficacy of Tumor Necrosis Factor-α Inhibitor Adalimumab in Chronic Recurrent Vogt–Koyanagi–Harada Disease2025 · 1 citations
4Oral methotrexate as a steroid-sparing therapy after high-dose intravenous corticosteroid pulse therapy for refractory Vogt–Koyanagi–Harada diseaseObservational Study · 2026
5Outcomes of early treatment in acute Vogt-Koyanagi-Harada disease: a 24-month retrospective analysisCohort Study · 2026